ACA
CRVS icon

Avoro Capital Advisors’s Corvus Pharmaceuticals CRVS Stock Holding History

Avoro Capital Advisors’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-121,715
Closed -$2.53M – 49
2017
Q1 		$2.53M Sell
121,715
-94,904
-44% -$1.49M 0.32% 34
2016
Q4 		$3.1M Sell
216,619
-51,750
-19% -$787K 0.63% 30
2016
Q3 		$4.42M Buy
268,369
+193,569
+259% +$2.79M 0.77% 29
2016
Q2 		$1.07M Hold
74,800
– – 0.24% 36
2016
Q1 		$1.08M Buy
+74,800
New +$1.07M 0.38% 32

Other funds holding CRVS

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $260M AUM 30.38% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Avoro Capital Advisors's CRVS Position: Q2 2017 in Review

Avoro Capital Advisors sold out of Corvus Pharmaceuticals (CRVS) in Q2 2017, closing a stake of 121,715 shares — an estimated $2.53M sold.

Avoro Capital Advisors first reported a position in CRVS in Q1 2016 and held it in 5 quarters. The position peaked at $4.42M in Q3 2016. 52 funds tracked by Wall St. Rank hold CRVS as of Q2 2017.

  • Avoro Capital Advisors reported no remaining Corvus Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
  • Avoro Capital Advisors sold 121,715 Corvus Pharmaceuticals shares in Q2 2017, an estimated $2.53M.
  • Avoro Capital Advisors first reported a position in Corvus Pharmaceuticals in Q1 2016 and held it in 5 quarters.
  • Avoro Capital Advisors's Corvus Pharmaceuticals position peaked at $4.42M in Q3 2016.
  • 52 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2017.

Based on Avoro Capital Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.